The Natural History and Function of T Follicular Helper Cells (T~FH~) and T Follicular Regulatory Cells (T~FR~) {#S1}
===============================================================================================================

T follicular helper cells were identified 16 years ago when CD4 T cells with a unique phenotype, notably abundant CXCR5 expression, were identified in the follicles and germinal centers (GCs) of secondary lymphoid tissues ([@B1]--[@B3]). T~FH~ express a unique transcriptional profile compared to extrafollicular and peripheral CD4 T cell subsets; they are a distinct population of CD4 T cells under the control of the master transcription regulator BCL-6 ([@B4]--[@B6]). T~FH~ rely on signaling through inducible T cell co-stimulator (ICOS), IL-21, IL-6, and STAT3 to develop and promote the GC response ([@B7]--[@B9]). Further, interactions with GC B cells support the development of CXCR5^hi^PD1^hi^ GC T~FH~ *via* sustained ICOS--ICOSL and CD40--CD40L binding ([@B10]). T~FH~ fail to accumulate in lymphoid tissues after immunization in the absence of B cells ([@B11]). T~FH~ provide help for maturation of B cells into plasma and memory subsets, as well as drive class switch recombination and expression of enzymes, such as activation-induced deaminase (AID) that promote somatic hypermutation (SHM) to generate highly mutated antibodies ([@B1]--[@B3]). T~FH~ are one of the main sources of IL-21, a key cytokine that promotes GC formation and maintenance, T~FH~ and B cell proliferation, SHM, and memory B cell/plasma cell differentiation ([@B12]--[@B15]). IL-21 is primarily produced by CD4 T cells and is particularly critical to generation of antigen-specific IgG antibodies and expansion of class-switched B cells and plasma cells *in vivo* \[reviewed in Ref. ([@B16])\]. T~FH~ produce a variety of other cytokines including IL-4 ([@B17]), IL-17 ([@B18]), and IFNγ ([@B19]). In addition, they express increased levels of IL-10, ICOS, and CD40L compared to other T helper subsets, which allows them to positively regulate B cell differentiation and function ([@B3], [@B20]). Due to constraints of studying T~FH~ from lymphoid tissues, recent studies have attempted to establish a marker for T~FH~ in blood ([@B21]). While several markers have been used to define peripheral T~FH~ (pT~FH~), several groups have used CXCR5 and PD1 co-expression ([@B22]--[@B24]). In rhesus macaques receiving a modified vaccinia virus Ankara SIV vaccine, it was shown that CXCR5+ CD4 T cells accumulated in the blood at peak effector response post-immunization, and proliferating (Ki-67 +) CXCR5+ CD4 T cells in blood were directly correlated to T~FH~ and GC B cell frequency in lymphoid tissues ([@B25]). Yet, direct functional studies comparing lymphoid T~FH~ to pT~FH~ have not been done, and their relation to each other, as discussed later, remains uncertain.

More recently, T~FR~ were identified as a unique CD4 T cell subset that controls and regulates GC responses ([@B26]--[@B28]). Similar to T~FH~, T~FR~ express high levels of Bcl-6, CXCR5, ICOS, and PD-1 ([@B26]--[@B29]). T~FR~ are unique in their ability to express Blimp-1 simultaneously with Bcl-6, and express high levels of Foxp3 compared to T~FH~ ([@B27]). T~FR~ develop independently of T~FH~ from natural Treg precursors, although they rely on similar signals as T~FH~, such as CD28 and ICOS, to differentiate ([@B27]). T~FR~ are a crucial component of the GC response as they inhibit GC expansion and regulate T~FH~ and GC B cell numbers to prevent development of autoimmunity ([@B26]--[@B28]). Recent studies have shown that the function of T~FR~ and/or a skew in the balance between T~FH~ and T~FR~ frequency can lead to impaired humoral immunity ([@B30]--[@B33]). Thus, an imbalance of the T~FR~-mediated GC regulation and skewing of the GC reaction may counteract this highly regulated response and dampen the immune response to pathogens.

T~FH~ Expand and are the Major Reservoir of HIV Replication in Chronic HIV Infection {#S2}
====================================================================================

In HIV infection prior to the development of AIDS, T~FH~ serve as the major site of virus replication ([@B34]--[@B37]). A CD4 T cell in the GC is on average 40 times more likely to be productively infected than a CD4 T cell outside of the follicle ([@B36]) and a median of 60--75% of HIV-producing cells are found within follicles in lymph nodes of untreated chronically HIV-infected individuals ([@B35], [@B36]). Within B cell follicles, the majority of HIV-producing cells are found in GC ([@B38]). Similarly, in chronically SIV-infected rhesus macaques without simian AIDS, virus replication is concentrated in B cell follicles in lymph nodes, spleen, and gut-associated lymphoid tissues, and these differences persist even after controlling for memory CD4 cell populations in the follicular and extrafollicular compartments ([@B39]).

Both heightened T~FH~ permissivity and factors in the follicular microenvironment play a role in promoting HIV replication within T~FH~. Tonsillar T~FH~ and GC T~FH~ are highly permissive to both X4- and R5-tropic HIV compared to other tonsillar T cell subsets *ex vivo* ([@B38], [@B40]). Heightened permissivity of T~FH~ is not fully explained by differences in memory subsets (as determined by CD95 expression), cellular activation (as measured by HLA-DR and CD38 expression), or chemokine HIV co-receptor expression ([@B38]). Within the microenvironment of the B cell follicle, specifically in the GC, follicular dendritic cells (FDC) bind HIV--antibody complexes *via* F~C~ and complement receptors ([@B41]). Although FDC are not productively infected, the virions bound to their surface are adjacent to T~FH~ within GCs ([@B41]--[@B43]), and these virions are highly infectious to T~FH~ ([@B42]), likely contributing to the high viral burden found in T~FH~. FDC further upregulate HIV replication in CD4 T cells through release of TNFα ([@B40]). A relative lack of cytotoxic T lymphocytes (CTL) in the follicle both in HIV ([@B36]) and SIV infection ([@B39], [@B44]), likely promotes replication at those sites. Most SIV-specific CTL lack a follicular homing phenotype (CXCR5+CCR7−), which may explain their failure to home to sites of virus replication in B cell follicles ([@B39]). Depletion of CD8 cells from SIV-infected macaques leads to increases in virus replication primarily in the extrafollicular zone, further supporting the notion that CTL are primarily active in the extrafollicular compartment and exert little antiviral activity within the follicle ([@B45]). Thus, T~FH~ are naturally highly susceptible to HIV, and their location within the immune privileged B cell follicle adjacent to FDC-bound virions further promotes high levels of HIV infection and replication.

Despite being highly permissive to HIV *ex vivo* and being the major virus-producing T cell subset in chronic HIV infection, the percentages of T~FH~ increase in early- and mid-stage chronic HIV ([@B37], [@B46]) and SIV infection ([@B47]). One of the hallmarks of HIV infection prior to AIDS is follicular hyperplasia. The follicles and GCs in HIV-seropositive lymph nodes are substantially larger in size than those in HIV-seronegative lymph nodes ([@B48]), suggesting that there are likely numerically more T~FH~ in HIV-seropositive compared to -seronegative lymph nodes in early and midstages of disease as well. Part of this expansion is likely antigen driven. In acute SIV infection, rapid formation of GC and accumulation of T~FH~, along with high p27 expression, in the follicle has been observed ([@B49]). In chronic HIV infection, virus-specific T~FH~ are expanded ([@B46]). It has been shown in mice that sustained antigenic stimulation from GC B cells is required to maintain the T~FH~ phenotype ([@B50]), further supporting the notion that antigen stimulation is key to T~FH~ expansion. It is likely that other factors besides antigen contribute to T~FH~ expansion. Cytokines known to promote T~FH~ survival, such as IL-6 ([@B47], [@B51]), and interferon-γ (IFN-γ) ([@B52], [@B53]), are increased in HIV and SIV infections, while IL-2, which inhibits T~FH~ differentiation, is decreased ([@B52]). Bcl-2, an anti-apoptotic protein, is upregulated on productively infected cells in *ex vivo* R5 infection ([@B54]). The cytokines present in the microenvironment of the T~FH~, as well as possible resistance to apoptosis, could therefore contribute to the expansion of the T~FH~ population.

T~FH~ Functional Impairments and Their Impact on Humoral Immunity During HIV Infection {#S3}
======================================================================================

T follicular helper cells provide B cell help *via* IL-21, IL-4, CD40L, and ICOS to drive antibody production by GC B cells ([@B55]). It was shown that T~FH~ and CXCR5−PD1+ CD4 T cell populations from viremic subjects can support IgG1, IgM, and IgA production *ex vivo* ([@B37]), but numerous examples of T~FH~ deficiencies have been demonstrated in HIV infection (Table [1](#T1){ref-type="table"}). B cell dysfunction has been well characterized during HIV infection, including the loss of memory B cell function, decreased numbers of GC B cells and plasma cells, hypergammaglobulinemia and spontaneous antibody production, and loss of T-dependent responses ([@B37], [@B56], [@B57]). Clinically, these deficits are manifested by increased vulnerability to bacterial infections as well as impaired responses to routine vaccinations. Increasing evidence has linked many of these deficits in humoral immunity to impaired T~FH~ function.

###### 

**T follicular helper cells (T~FH~) functional impairments during HIV infection**.

  T~FH~ definition               Compartment   Treatment   Impairment                                                                                                                                                                                       Reference
  ------------------------------ ------------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------
  CD4+CXCR5+PD-1^hi^             Lymph node    Y/N         Lower Env-specific responses than Gag-specific responses; decreased Bcl-6 expression after antiretroviral therapy (ART); increased transitional B cells; hypergammaglobulinemia                  ([@B46])
                                                                                                                                                                                                                                                            
  CD4+CD45RA−CXCR5+PD-1+Bcl-6+   Lymph node    Y/N         Higher Gag- and Pol-specific than Env-specific responses; harbor high levels of HIV DNA                                                                                                          ([@B37])
                                                                                                                                                                                                                                                            
  CD4+CD45RA−CXCR5^hi^           Lymph node    N           Lower of proliferation, ICOS expression, IL-21, IL-10, and IL-4 production after PD-1 ligation                                                                                                   ([@B58])
                                                                                                                                                                                                                                                            
  CD4+CD45RA−CCR7−CXCR5+         Spleen        N           Expansion coinciding with increased transitional B cells and lower memory B cells; disrupted transcriptional profiles in HIV-infected subjects; high levels of DNA integration                   ([@B59])
                                                                                                                                                                                                                                                            
  CD4+CXCR5+CCR6+CCR7+PD1+       Blood         Y/N         T~FH~ decrease in treatment-naïve subjects; increase with ART but not to healthy control levels; low IL-4 production; weak supporters of IgG production                                          ([@B24])
                                                                                                                                                                                                                                                            
  HIV-specific, IL-21+CD4+       Blood         N           Lower breadth and magnitude of HIV-specific responses compared to IFNγ+CD4 T cells; no HIV-specific peripheral TFH responses in patients with higher viral loads                                 ([@B60])
                                                                                                                                                                                                                                                            
  CD4+CXCR3−CXCR5+PD-1+          Blood         N           Not all CXCR5+ cells promote B cell help, only CXCR3− subsets; high T~FH~ frequency led to higher antibody neutralization scores but not decreased viral loads                                   ([@B23])
                                                                                                                                                                                                                                                            
  CD3+CD4+CD45RA−CXCR5+CXCR3−    Blood         Y/N         Diminished B cell help during acute infection progression; increased TNFα and decreased IL-10 production that both correlate to decreased HIV-specific IgG production and increased viral load   ([@B61])

*A summary of studies from individuals with HIV infection, including the definition of T~FH~ used, the location of T~FH~, and a brief description of their key functional impairments*.

In chronic SIV infection, a marked increase of proliferation and turnover of GC B cells was seen as T~FH~ accumulated ([@B49]). T~FH~ from lymph nodes of HIV-infected subjects did not produce IL-21 upon HIV antigen stimulation, but were able to after PMA/ionomycin stimulation ([@B37]). T~FH~ have high levels of Ki-67 expression but low rates of proliferation in uninfected tonsils ([@B55]) and HIV-infected lymph nodes ([@B37]). However, IL-21 levels have been reported as deficient in HIV-infected subjects ([@B62]), and a longitudinal study demonstrated that HIV-specific IL-21+ CD4 T cells are decreased in viremic subjects ([@B63]). In this study, only elite controllers maintained high levels of IL-21 production, and antiretroviral therapy (ART) only partially restored IL-21 levels ([@B63]). Interestingly, IL-21+ CD4 T cells from HIV-infected patients have low levels of CD40L expression ([@B64]). The loss of CD40--CD40L interactions could lead to impaired stimulation of B cells by CD4 T cells from viremic HIV-infected subjects ([@B65]). In another study, splenic T~FH~ from HIV-infected subjects demonstrated impairments in IL-4 production, along with reductions in CD40L and ICOS gene expression ([@B59]). Recently, it was demonstrated that chronically SIV-infected rhesus macaques have an expansion of Th1-biased GC T~FH~, phenotypically distinct from conventional GC T~FH~, which express CXCR3, produce high levels of IFNγ, and contain higher levels of SIV RNA ([@B66]).

Impact of Altered T~FH~ Function on Anti-HIV Antibody Response {#S4}
==============================================================

Deficits in T~FH~ likely contribute to the failure to develop effective antibody responses to HIV. A recent study of acute HIV seroconverters demonstrated the onset of impairments in the ability of circulating T~FH~ to stimulate HIV-specific antibody production by B cells are associated with peak viremia, suggesting that T~FH~ defects occur very early following infection ([@B61]). Most antibodies generated during infection that neutralize across clades of HIV, i.e., broadly neutralizing antibodies (bnAb), are generated after several years and show high levels of SHM resulting from extensive affinity maturation in the GC. These responses are only generated in a small fraction of infected individuals ([@B67]), and the critical components of bnAb generation are unknown ([@B68]). In both untreated and treated HIV-infected subjects, T~FH~ from lymph nodes were shown to be on average five times more sensitive to Gag than Env, with overall low T~FH~ cytokine production after Env stimulation ([@B46]). This could be due to the increased presence of Gag antigen compared to Env antigen in the lymph node of HIV-infected subjects ([@B69]) and the persistence of p24 antigen in lymph nodes after long-term ART ([@B70]). While it is not surprising there are more Gag-specific T~FH~ than Env-specific T~FH~, a lack of specificity to the HIV envelope by T~FH~ is likely one of the contributing factors to a lack of bnAb development. A loss of Gag-specific antibody response occurs during disease progression, but there is no simultaneous increase of high affinity Env-specific response ([@B71]). Thus, an early and sustained lack of Env-specific T~FH~ response could contribute to the slow development of HIV-neutralizing antibody responses and with the failure of many individuals to generate bnAbs.

While protective neutralizing antibodies and bnAbs have been structurally and genetically well characterized in HIV-infected individuals, it remains unclear how these antibodies are generated and whether or not T~FH~ can promote bnAb development. The development of bnAbs is relatively slow and shown to not strongly correlate with CD4 T cell counts, MHC II alleles, or typical patient demographics ([@B72]). However, some evidence suggests that T~FH~ function plays a role in HIV neutralization. Circulating CD4 T cells from HIV controllers and ART-treated individuals produced IL-21 when stimulated with an HIV peptide pool, but not those from HIV progressors ([@B73]). In a longitudinal assessment of acute HIV infection (12 months), treated individuals had consistently higher IL-21 production than untreated individuals, and IL-21 contributed to viral control in CD4 and CD8 T cell co-cultures *ex vivo* ([@B73]). In a cohort of chronic aviremic subjects, IL-21 production was reduced in circulating T~FH~ and supplementation of IL-21 or replacement of these subjects' T~FH~ with T~FH~ from healthy controls led to increased production of HIV-specific antibodies by B cells *ex vivo* ([@B74]). In a cohort of HIV-infected individuals a limited proportion of patients developed bnAbs, but these patients had the highest levels of circulating, functional memory T~FH~ ([@B23]). However, their viral loads did not decline after 4 weeks, but began to decline in a few individuals at 40 weeks ([@B23]). T~FH~ frequency correlated strongly with bnAb development, thus indicating that T~FH~ are important for generating bnAb. In HIV-infected children receiving ART, circulating memory T~FH~ declined, expressed low levels of ICOS, and had a diminished capacity to produce IL-4 ([@B75]). Thus, impairments of T~FH~ function can persist in the absence of viremia. Further, in SHIV-infected rhesus macaques, the quality of T~FH~ response was correlated with the degree of SHM in virus-specific B cells and bnAb production ([@B60]). As virus-specific IL-4+ T~FH~ increased (IL-21 was not measured in this study), the amount of IgG+ virus-specific B cells and neutralizing response against HIV increased ([@B60]). Specifically, the frequency of IL-4+ and CD40L+ T~FH~ correlated strongly with the frequency of Env-specific IgG + B cells ([@B60]). This study also identified a population of IFNγ+ Env-specific T~FH~, which are less likely to provide B cell help, and these did not correlate to Env-specific IgG+ B cells. In another study, IL-21+ CD4 T cells in the periphery of HIV-infected individuals were shown to be functionally and transcriptionally equivalent to T~FH~, and Env-specific IL-21+ CD4 T cells provided higher quality B cell help than the Gag-specific subset. Env-specific IL-21+ CD4 T cells also positively correlated to protective responses of subjects who responded to vaccination in the RV144 study ([@B76]). Thus, eliciting the right type of T~FH~ help, rather than broad T~FH~ activation, is crucial to bnAb generation. Augmentation and promotion of T~FH~ function to boost this Env-specific IL-21+ CD4 T cell response could benefit future preventive vaccine trials and lead to broader specificity of anti-HIV antibodies and perhaps promote more rapid development of bnAbs in vaccinated individuals.

T~FH~ Impairment and Their Relationship to Vaccine Responses in HIV-Infected Individuals {#S5}
========================================================================================

Individuals with chronic HIV infection typically produce poor antibody responses to immunization ([@B77]) and specifically had a high failure rate after a dose of the H1N1/09 influenza vaccine ([@B78]). In HIV seronegative individuals, the emergence of blood ICOS+CXCR5+CXCR3+ T~FH~ that are able to produce IL-21 correlated with influenza-specific B cell responses ([@B79]) and blood ICOS+IL-21+ influenza-specific T~FH~ expand after immunization and correlate to antibody responses ([@B80]). T~FH~ function in HIV-infected individuals could be important to respond to vaccinations, but research in this area is limited. In ART-treated HIV-infected individuals, responders to the H1N1/09 influenza vaccine had upregulated IL-21 production and increased IL-21 receptor expression on B cells ([@B81]). Further, B cells from HIV-infected influenza responders secreted high levels of IgG after stimulation with IL-21 and H1N1 antigen, whereas HIV-infected non-responders did not ([@B81]). Expression of AID was positively correlated to influenza neutralizing antibody responses in HIV-infected individuals, and those with the highest levels of AID expression carried protective antibodies for the longest amount of time ([@B82]).

Recently, the quality of T~FH~ responses to influenza vaccination was characterized in HIV-infected individuals. Of 16 HIV-infected subjects on ART receiving the H1N1/09 influenza vaccine, 8 subjects responded. Antibody responses were linked to the ability of pTFH to proliferate, to the ability of pT~FH~ in responders to proliferate, produce IL-21, and stimulate IgG production ([@B22]). In this study, pT~FH~ were not significantly altered in HIV-infected subjects and healthy controls at the time of vaccination, and the HIV-infected group had significantly higher frequencies of central memory pT~FH~ ([@B22]). These data indicate that although pT~FH~ were phenotypically similar in HIV-infected subjects compared to healthy controls, recall response and function of pT~FH~ is significantly impaired in HIV-infected subjects even after potent ART regimens. As B cell/pT~FH~ cocultures were performed with sorted cells it remains to be determined if T~FR~ in the periphery play a role in the dichotomy of HIV-infected responders and non-responders.

Mechanisms That Underlie T~FH~ Dysfunction {#S6}
==========================================

One of the obvious causes of T~FH~ dysfunction is direct HIV infection of the T~FH~ themselves. Nevertheless, only a minority of T~FH~ are producing virus at any single time point ([@B36]), and thus this is unlikely to be the principal cause of their dysfunction. T~FH~ are characterized by high levels of PD-1 expression. Ligation of PD-1 on T~FH~ by lymph node B cells that express PD-L1, which are elevated in HIV-infected individuals, leads to decreases in IL-21 production and ICOS expression ([@B58]). Blockade of this interaction, with PD-L1 neutralizing antibodies, restores T~FH~ help to B cells and promotes IgG production ([@B58]). One report has shown that HIV infection leads to an expansion of PD-L1 expressing regulatory B cells in peripheral blood that positively correlate with increased viral load and T cell exhaustion ([@B83]), however, T~FH~ function was not examined.

Another likely cause of T~FH~ dysfunction in HIV infection is regulation by T~FR~. In mice, the magnitude of the GC reaction increased and autoimmune responses were generated when T~FR~ were unable to migrate into the follicle ([@B84]). Also in mice, it was demonstrated that excessive numbers of T~FH~ are correlated with impaired affinity maturation, and restoring a balanced ratio of T~FH~ to T~FR~ allows for generation of highly mutated, high avidity antibodies ([@B85]). Recent studies in rhesus macaques have shown that T~FR~ frequencies in secondary lymphoid tissues are increased in chronically SIV-infected animals ([@B48], [@B86]), while another study found decreases in T~FR~ during chronic infection ([@B87]). Reasons for discrepancies among these studies are not clear. In chronic HIV infection, T~FR~ are increased in lymph nodes ([@B48]) and spleen ([@B59]). They are also increased during acute *ex vivo* HIV infection of tonsil cells ([@B48]). In *ex vivo* HIV infection of human tonsil cells, our group found that T~FR~ inhibited ICOS expression, IL-21 production, and IL-4 production by T~FH~ ([@B48]). In another study of treatment-naïve, chronically HIV-infected subjects, the frequency of memory (CD45RA-CCR7-) T~FR~ and T~FH~ were shown to increase ([@B59]). These increases were associated with increased GC B cells; however, these cells were mostly naïve, pre-GC, and transitional B cells as opposed to memory B cells ([@B59]). Increases in T~FH~ and T~FR~ from spleen cells of HIV-infected subjects were associated with defects in the memory B cell compartment and reduced B cell help factors such as IL-4 ([@B59]). In addition, higher quality of Env-specific (gp120) antibodies in SIV-infected rhesus macaques was correlated with a lower frequency of T~FR~ ([@B87]). Neutralizing antibodies to HIV were negatively correlated to Foxp3+ Env-specific T~FH~ (T~FR~ were not excluded from T~FH~ in this work) in SHIV-infected rhesus macaques ([@B60]). Collectively, these data suggest that human T~FR~ increase during chronic HIV infection and impair T~FH~ function resulting in disruption of proper B cell differentiation and SHM. It has been shown in mouse models that the loss of T~FR~ function allows for higher levels of antibody production, but the resulting antibody is much lower affinity than if T~FR~ function is not impaired ([@B32]). Whether T~FR~ are able to control B cell responses directly, through T~FH~ impairment, or both remains to be shown.

Memory T~FH~ in HIV-Infected Individuals {#S7}
========================================

One clear area requiring more research is the development and fate of memory T~FH~ subsets. It is currently unknown if T~FH~ memory forms and is sustained inside or outside of the GC, or whether effector T~FH~ persist in chronic infections due to prolonged antigen exposure and GC maintenance ([@B88], [@B89]). This is especially difficult to distinguish in HIV-infected subjects, as high levels of antigens persist in the lymph nodes well after ART initiation. Effector T~FH~ are present as long as the GC persists, but if these cells become memory T~FH~ or influence the response to vaccinations in HIV-infected subjects remains to be determined. One challenge in defining memory T~FH~ and effector T~FH~ is the plasticity of phenotype of these cells. Studies in LCMV-infected mice have demonstrated that CXCR5+ memory T~FH~ downregulate PD-1, Bcl-6, IL-21, and ICOS compared to effector populations, but are able to recall effector T~FH~ phenotype upon antigen challenge, suggesting a T~FH~ lineage commitment of these memory cells ([@B90], [@B91]). CXCR5 has been used to distinguish memory T~FH~, but not all CXCR5+ CD4 T cells possess T~FH~ function after activation ([@B23]). Furthermore, in a mouse model, T~FH~ lost expression of Bcl-6, CXCR5, and PD-1 and acquired a memory phenotype when transferred into a mouse that did not express the cognate antigen ([@B92]). Thus, lack of a reliable phenotype for effector and memory T~FH~ populations remains a barrier to studying memory T~FH~ development and assessing memory responses ([@B93]).

Another important question is the location of the memory T~FH~ pool and whether there is crosstalk between blood and lymphatic tissues. It has been shown that circulating and lymph node-resident memory populations may develop independently and both are antigen specific with potent effector functions ([@B94], [@B95]). In mice, it was demonstrated that effector T~FH~ can circulate to various GCs within the same lymph node, but rarely escape to the periphery ([@B94]). Further, pT~FH~ with memory function were shown to develop independent of the GC in mice ([@B96]). As sampling pT~FH~ in the blood is more feasible than lymph node T~FH~ and circulating T~FH~ are shown to have memory and migrate to lymph nodes to stimulate B cell effector responses ([@B95]), most studies to date have focused on the function of pT~FH~ in vaccine responses of HIV-infected subjects. Highly functional pT~FH~ are reduced in viremic HIV-infected subjects, but rebound after the administration of ART ([@B24]). In this study, abundance of IgG+ memory B cells and neutralizing antibody did not strongly correlate with pT~FH~ frequency, however, pT~FH~ from HIV-infected subjects had relatively low IL-21 production in response to either SEB or Gag peptide pool stimulations and had low levels of IL-21 and IL-4 gene expression ([@B24]). This suggests that humoral responses and vaccine responses not only need to boost pT~FH~/T~FH~ numbers, but also elicit highly functional B cell help responses.

The extent to which HIV directly influences T~FH~ function, or whether HIV-driven enhancements in T~FR~ regulatory activity influences T~FH~ dysfunction, leading to poor memory and vaccine response, remains to be fully understood. In mice, circulating T~FR~ were shown to be expanded after viral infection and could potently suppress pT~FH~ function without requiring specific antigens ([@B95]). Whether T~FR~ prevent memory T~FH~ function, or prevent memory T~FH~ from reacquiring effector T~FH~ function, is an important area of future research. As T~FR~ frequency has been found to negatively correlate with bnAb generation ([@B60], [@B87]), it will be necessary to determine if they also disrupt the formation or activation of memory T~FH~. T~FR~ could prevent memory T~FH~ from having high quality effector responses and thus represent a barrier to generating effective vaccine responses. T~FR~ regulatory function could impair the activity of memory T~FH~ and be one of the contributing factors to failure of preventative HIV vaccinations. Further, as T~FR~ act non-specifically on target cells, they could also contribute to the relatively low efficacy of non-HIV vaccine responses in HIV-infected individuals.

Conclusion {#S8}
==========

T follicular helper cells have a critical role in HIV immunopathogenesis. They proportionately expand compared to total CD4 T cells during chronic disease and are the major virus-producing cells during asymptomatic disease, thereby driving disease progression. They also exhibit multiple functional deficits that impair development of robust humoral immunity to pathogens, including HIV itself. Mechanisms underlying T~FH~ impairment likely include direct infection of T~FH~, suppressive factors in the GC milieu such as PD-L1 expression on B cells, and T~FR~. Strategies to augment T~FH~ immunity remain to be developed, but potential interventions include administration of IL-21 as well as inhibition of T~FR~ responses. Such strategies need to be developed cautiously as unintended consequences of these interventions, such as development of autoimmunity due to excessive inhibition of T~FR~, could be deleterious. A better understanding of the nature of memory T~FH~ populations is also essential in order to develop and test interventions. Knowledge of factors that influence T~FH~ function in HIV infection could lead to improved immune reconstitution in ART-treated individuals and potentially augment strategies to cure HIV infection.
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